2411-77-0

Basic information

• Product Name: 1-Methyl-4-phenyl-1H-iMidazole
• Synonyms: 1-Methyl-4-phenyl-1H-iMidazole;1-methyl-4-phenylimidazole
• CAS NO: 2411-77-0
• Molecular Formula: C₁₀H₁₀N₂
• Molecular Weight: 158.1998
• Mol File: 2411-77-0.mol
• Article Data: 23

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Methyl-4-phenyl-1H-iMidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Methyl-4-phenyl-1H-iMidazole(2411-77-0)
• EPA Substance Registry System: 1-Methyl-4-phenyl-1H-iMidazole(2411-77-0)

Safety Data

• Hazardous Substances Data: 2411-77-0(Hazardous Substances Data)

Usage

Type of compound

Chemical compound, derivative of imidazole

Common uses

Biochemical and pharmaceutical research

Potential applications

Ligand in metal complexes, precursor in organic synthesis, building block for pharmaceutical compounds

Therapeutic potential

Neuroprotective properties, studied for treatment of neurological disorders such as Parkinson's disease

Physical properties

White crystalline solid at room temperature

Solubility

Soluble in organic solvents such as ethanol and diethyl ether

Upstream product

• 93782-03-7 1-methyl-4-phenyl-1,3-dihydro-imidazol-2-one 
• 25433-14-1 1-methyl-4-phenyl-1,3-dihydroimidazole-2-thione 
• 38036-86-1 N-acetyl-4⁽⁵⁾-phenylimidazole 
• 74-88-4 methyl iodide 
• 10199-69-6 1-methyl-4-phenyl-1H-pyrazole 
• 670-95-1 4-Phenylimidazole 
• 77-78-1 dimethyl sulfate 
• 3463-27-2 1-methyl-5-phenyl-1H-pyrazole 
• 70205-68-4 (Z)-3-(N-methylamino)-2-phenylpropenenitrile 
• 6297-94-5 2-benzylsulfanyl-4-phenyl-1⁽³⁾H-imidazole 
• 25676-75-9 4-bromo-1-methyl-1H-imidazole 
• 5123-13-7 5,5-dimethyl-2-phenyl-1,3,2-dioxaborinane 
• 591-51-5 phenyllithium 
• 71759-87-0 4-iodo-1-methyl-1H-imidazole 

Downstream Products

• 41217-55-4 1,3-dimethyl-4-phenyl-1H-imidazol-2-ium iodide 
• 141264-27-9 N'-benzoyl-N-methyl-N-formylurea 
• 196810-82-9 2-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethanol 
• 123511-51-3 1-methyl-4-phenyl-1H-imidazole-2-carbaldehyde 
• 1083051-76-6 4-hydroxy-4-(1-methyl-4-phenyl-1H-imidazol-2-yl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1438258-15-1 2-(2-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethyl)-5-morpholino-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1438258-14-0 5-bromo-2-(2-(1-methyl-4-phenyl-1H-imidazol-2-yl)ethyl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one 
• 1429781-97-4 2-methyl-4-(1-methyl-4-phenyl-1H-imidazol-2-yl)-but-3-yn-2-ol 
• 1429781-96-3 2-iodo-1-methyl-4-phenyl-1H-imidazole 
• 1429781-98-5 2-ethynyl-1-methyl-4-phenyl-1H-imidazole 
• 1429781-54-3 2-methyl-4-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-pyrido[2,3-d]pyrimidine 
• 1429781-12-3 2-methyl-4-(1-methyl-4-phenyl-1H-imidazol-2-ylethynyl)-pyrido[2,3-d]pyrimidine 
• 1429780-95-9 5-fluoro-4-methyl-2-(1-methyl-4-phenyl-1H-imidazol-2-ylethynyl)-quinazoline 
• 1185580-48-6 3-benzyl-1-methyl-4-phenylimidazolium bromide 

Relevant articles and documents

3-(AZOLYLMETHOXY)BIPHENYL DERIVATIVES AS INHIBITORS OF THE PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION

The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-1/PD-L1 protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative diseases such as schizophrenia, Alzheimer, multiple sclerosis or Parkinson.

Design, Synthesis, and Application of Polymer-Supported Silicon-Transfer Agents for Cross-Coupling Reactions with Organolithium Reagents

The initial design, synthesis, and validation of polymer-supported siloxane transfer agents have been achieved that permit the direct use of organolithium reagents in the palladium-catalyzed cross-coupling reactions. Through rational design, two generations of polymer support were developed that significantly simplify product purification and the transfer agent recycling.

TRIAZOLOPYRIDINONE PDE10 INHIBITORS

The present invention is directed to triazolopyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.